ARVEN İlaç began operating at the end of 2013, planning to work first in the treatment of respiratory diseases and, in the near future, diseases requiring biotechnology products. It shapes its work around forward-looking respiratory and biotechnology expertise and a safe-treatment principle.
Together with Sanovel, ARVEN İlaç is part of Toksöz Group, with the aim of becoming one of the most important organisations in the Turkish pharmaceutical industry, with international-standard scientific and technological infrastructure, human resources and high production capacity. It plans to add new products to its respiratory and biotechnology portfolio in the near future.
The company has a production facility on a 30,000 m2 site in Kırklareli, which began operating in 2017, and an R&D facility in Selimpaşa. Together they employ approximately 200 people.
Medical pharmaceuticals
🔒 Log in to Send Inquiry
No account yet? Register free — it takes under a minute.
Log in to save to favourites 💳 Claim this listing
